100% agree. Living in SE Asia over a decade and with dengue in...

100% agree. Living in SE Asia over a decade and with dengue in our area throughout the year, you get a real appreciation for what ISLA-101 can be. I have had friends hospitalised and I have had friends get dengue a second time, all these support both a treatment and a preventative (especially if you have had dengue).
Treatment options here have reduced with the main drug used here being taken out of the market. Any suspected dengue case they load you up on antivirals immediately even before they have the blood tests back. So it is serious here.

2b, I believe will be a lead in to a larger field trial I am presuming in SE Asia or South America would be potential targets. But they will want some data showing activity before they are going to let Island do this and I this was the aim of 2B.. Dengue is like the flu, different people have different experiences and recover in different timeframes. Add in a weakened strain and a day 7 treatment start, I don't believe it will be a slam dunk visible recovery but the data will show peak viral load abating. But you should also see it start to abate in the placebo as peak viral load is around 8-10 days in people with good immunity systems.

Question really becomes in a normal strain does it stop hospitalisation and the viral load continuing to build, what happens in people that have had dengue before. In those cases we get antibody-dependent enhancement (ADE). This occurs because pre-existing antibodies from the first infection, while not neutralizing the new, different dengue virus strain, can actually help it enter immune cells and replicate more efficiently, leading to increased viral load and potentially more severe symptoms. If ISLA-101 can reduce this viral load it should lead to a better outcome in these patients.

My thoughts only. Not investment advice.